Trial · NCT03989206
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and Severity of TEAEs | Baseline to Week 200 | |
| Primary | Incidence of Serious TEAEs | Baseline to Week 200 | |
| Primary | Incidence and Severity of Adverse Events of Special Interest (AESIs) Throughout the Study | Baseline to Week 200 | |
| Secondary | Proportion of Participants with IGA score = 0-1 at Each Visit | Baseline to Week 200 | |
| Secondary | Proportion of Participants with EASI-75 at Each Visit | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in Overall Eczema Area and Severity Index (EASI) Score at Each Visit | Baseline to Week 200 | EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity will be assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score can range from 0 to 72 with higher scores representing greater severity of atopic dermatitis. |
| Secondary | Proportion of Participants with IGA ≤ 2 at Each Visit | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in SCORAD Score at Each Visit | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in Participant-Reported Pruritus Using 10-cm VAS (SCORAD Sub-Component) | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in Participant-Reported Sleep Loss Using 10-cm VAS (SCORAD Sub-Component) | Baseline to Week 200 | |
| Secondary | Proportion of Participants Reporting Low Disease Activity State Based on PGAD at Each Visit | Baseline to Week 200 | |
| Secondary | Proportion of Participants Satisfied with Study Treatment Based on PGAT at each visit | Baseline to Week 200 | |
| Secondary | Change from Baseline in Dermatology Life Quality Index (DLQI) | Baseline to Week 200 | |
| Secondary | Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Total Score at Each Visit Through Week 200 | Baseline to Week 200 | |
| Secondary | Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Each Visit Through Week 200 | Baseline to Week 200 | |
| Secondary | Change From Baseline in Hospital Anxiety and Depression Scale (HADS) for Each Subscale at Each Visit Through Week 200 | Baseline to Week 200 | |
| Secondary | Change From Baseline in Work Productivity and Activity Impairment: Atopic Dermatitis (WPAI:AD) for Each Subscale at Each Visit Through Week 200 | Baseline to Week 200 | |
| Secondary | Change From Baseline in EuroQoL 5-Dimension (EQ-5D) at Each Visit Through Week 200 | Baseline to Week 200 | |
| Secondary | Proportion of Participants Receiving Any Rescue Therapy by Rescue Treatment Type at Any Visit During the Treatment Period | Baseline to Week 200 | |
| Secondary | Time to First Relapse | Baseline to Week 200 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03989206/registered